This issue is vital, because newer generations of antidiabetic medications constitute the main pillars of therapies (eg, sodium-glucose cotransporter-2 inhibitors and others), and there are concerns that these medications may alter frailty or sarcopenia severity.24 Here, SLC5A2 is linked to sarcopenia.